Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 1;14(7):2407.
doi: 10.3390/jcm14072407.

Modest NT-proBNP Elevation in Septuagenarians Without Heart Failure Is Not Associated with Cardiac Alterations or Cardiovascular Outcomes

Cristina Oliveira da Silva  1   2 , Camilla Hage  1   2 , Jonas Johnson  1 , Magnus Bäck  1   2 , Anikó I Nagy  2   3 , Emma Svennberg  2   4 , Larissa Bastos  5 , Johan Engdahl  5 , Faris Al-Khalili  5 , Lars Lund  1   2 , Aristomenis Manouras  1   2
Affiliations

Modest NT-proBNP Elevation in Septuagenarians Without Heart Failure Is Not Associated with Cardiac Alterations or Cardiovascular Outcomes

Cristina Oliveira da Silva et al. J Clin Med. .

Abstract

Background/Objectives: To assess the association between moderate N-terminal natriuretic peptide (NT-proBNP) and cardiac alterations and prognosis in septuagenarians without heart failure (HF). Methods: From the STROKESTOP II screening study, 230 individuals aged 75/76 years with NT-proBNP < 900 ng/L were randomly selected. Subjects with persistent atrial fibrillation (AF), more than mild valvular disease, or HF were excluded. Echocardiography was performed. NT-proBNP ≥ 125 ng/L and paroxysmal AF (pAF) on thumb ECG were used as grouping variables. Participants were followed up during a median of 5 years for cardiovascular mortality, HF, AF, and cerebrovascular events. Cox regression analysis was employed for prognostic assessment. Results: Three groups were identified: SR ≥ 125 (n = 94, no pAF and NT-proBNP ≥ 125 ng/L), pAF (n = 77, pAF and NT-proBNP ≥ 125 ng/L), and controls (n = 30, no pAF and NT-proBNP < 125 ng/L). NT-proBNP was not associated with structural (left atrial volume and left ventricular (LV) mass) or functional (E/e', LV strain) alterations in any group (p > 0.05). Cardiovascular risk factors (HR: 4.6; CI = 1.7-12.3; p = 0.002), but not NT-proBNP (HR: 1.9; CI = 0.7-5.1; p = 0.2), entailed a prognostic value for the composite endpoint of HF, AF, and cardiovascular death. Conclusions: In septuagenarians without HF, modest NT-proBNP elevation was not associated with echocardiographic changes or prognosis.

Keywords: N-terminal pro-brain natriuretic peptide; age; atrial fibrillation; echocardiography; heart failure.

PubMed Disclaimer

Conflict of interest statement

Emma Svennberg is supported by the Stockholm County Council (Clinical researcher appointment), the Swedish Research Council (DNR 2022-01466), the Swedish Heart and Lung foundation, and CIMED, and has received lecture fees from Bayer, Bristol-Myers Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, and Merck Sharp & Dohme. Johan Engdahl has received consultant or lecture fees from Roche Diagnostics, Pfizer, Bristol Myers Squibb, Boehringer Ingelheim, Piotrode, and Philips. Research grants were received from the Swedish Research Council, the Swedish Heart and Lung Foundation, the Swedish Innovation Agency, and the Stockholm Region. Faris Al-Khalili has received consultant or lecture fees from Pfizer, Bristol Myers Squibb, and Boehringer Ingelheim Anikó I. Nagy was funded by the K-146732 OTKA grant of the Hungarian National Research Development and Innovation Office.

Figures

Figure 1
Figure 1
NT-proBNP levels in patients without and with morphological and functional abnormalities. Cumulative score of cardiac abnormalities was calculated as recommended by Pieske et al. (A) Cohorts without paroxysmal atrial fibrillation (pAF), (B) patients with pAF [12].
Figure 2
Figure 2
Diastolic function and filling pressure assessment.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Bohm M., Burri H., Butler J., Celutkiene J., Chioncel O., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021;42:3599–3726. doi: 10.1093/eurheartj/ehab368. - DOI - PubMed
    1. Natriuretic Peptides Studies Collaboration. Willeit P., Kaptoge S., Welsh P., Butterworth A.S., Chowdhury R., Spackman S.A., Pennells L., Gao P., Burgess S., et al. Natriuretic peptides and integrated risk assessment for cardiovascular disease: An individual-participant-data meta-analysis. Lancet Diabetes Endocrinol. 2016;4:840–849. doi: 10.1016/S2213-8587(16)30196-6. - DOI - PMC - PubMed
    1. Huelsmann M., Neuhold S., Resl M., Strunk G., Brath H., Francesconi C., Adlbrecht C., Prager R., Luger A., Pacher R., et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): A prospective randomized controlled trial. J. Am. Coll. Cardiol. 2013;62:1365–1372. doi: 10.1016/j.jacc.2013.05.069. - DOI - PubMed
    1. Ledwidge M., Gallagher J., Conlon C., Tallon E., O’Connell E., Dawkins I., Watson C., O’Hanlon R., Bermingham M., Patle A., et al. Natriuretic peptide-based screening and collaborative care for heart failure: The STOP-HF randomized trial. JAMA. 2013;310:66–74. doi: 10.1001/jama.2013.7588. - DOI - PubMed
    1. Knebel F., Eddicks S., Schimke I., Bierbaum M., Schattke S., Beling M., Raab V., Baumann G., Borges A.C. Myocardial tissue Doppler echocardiography and N-terminal B-type natriuretic peptide (NT-proBNP) in diastolic and systolic heart failure. Cardiovasc. Ultrasound. 2008;6:45. doi: 10.1186/1476-7120-6-45. - DOI - PMC - PubMed

LinkOut - more resources